Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- Opdivo Approval for Head and Neck Cancer Expected in Late March-Early April
March 6, 2017
- MHLW Advisory Committee OKs Ninlaro, Sovaldi for Genotypes 3-6
March 6, 2017
- MHLW OKs Add’l Indications for Revlimid, Other Drugs
March 3, 2017
- Orphan Status Dropped for 3 Drugs, Designation Given to Canakinumab
March 3, 2017
- Industry Reps Call for Early Discussions on Inclusion of Vaccines in Public Vaccination Programs: Hearings
March 3, 2017
- MHLW Advisory Panel Backs Shionogi’s Pediatric ADHD Drug
March 3, 2017
- New CEFP Working Group on Assessment and Analysis Launches Discussions
March 2, 2017
- Non-Partisan Lawmaker Group on Healthcare Boots Up, Plans Fortnightly Hearings
March 2, 2017
- MHLW to Tap NCCHD Database to Improve Pediatric Drug Use Environment
March 2, 2017
- Conduct Surprise Inspections on Wholesalers/Pharmacies by March-End, MHLW Asks Pref. Authorities
March 2, 2017
- MHLW OKs 53 NMEs in 2016
March 2, 2017
- 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations
March 2, 2017
- MHLW Summons NHK, MSD over Misleading TV Program
February 28, 2017
- Pros and Cons for Setting Up “International Center for Regenerative Medicine”: LDP, Komeito Lawmakers
February 27, 2017
- AMED to Deploy “Site Coordinators” to Expedite Drug Discovery
February 24, 2017
- Is “No Gx Substitution” Column in Scripts Still Necessary? Asks Chuikyo Payer Rep
February 23, 2017
- Foreign Price Adjustment Doesn’t Make Much Sense for Drugs with Similar Meds in Japan: Industry
February 23, 2017
- Overhaul Rules to Pick Comparator Meds in Similar Drug Pricing Method: Chuikyo Rep
February 23, 2017
- Council Drafts Scheme to Provide Unapproved Drugs in Response to Infectious Disease Outbreaks in Developing Countries
February 23, 2017
- Use of Generic Drugs Increases, Lingering Concerns Over Quality: Survey
February 23, 2017
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…